Immix Biopharma (IMMX) Retained Earnings (2020 - 2026)
Immix Biopharma (IMMX) reported Retained Earnings of -$114.5 million for Q1 2026, down 740900.43% on a YoY basis from N/an in Q1 2025, and down 9.66% sequentially from -$104.5 million in Q4 2025.
Immix Biopharma (IMMX) Retained Earnings (2020 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 7 years of Retained Earnings data on file, last reported at -$114.5 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 740900.43% year-over-year to -$114.5 million; the trailing twelve-month figure through Mar 2026 stood at -$114.5 million (down 740900.43% YoY), and the FY2025 full-year result was -$104.5 million, down 9892256.44% from the prior year.
- Retained Earnings eased to -$114.5 million in Q1 2026, from -$104.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $90.9 million in Q2 2025 to a low of -$114.5 million in Q1 2026.
- A 5-year average of -$5.6 million and a median of $82547.0 in 2023 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 77589.43% in 2025, while the deepest fall reached 9892256.44% in 2025.
- Tracing IMMX's Retained Earnings over 5 years: stood at -$38.0 million in 2022, then surged by 100.35% to $134666.0 in 2023, then tumbled by 100.78% to -$1056.0 in 2024, then slumped by 9892256.44% to -$104.5 million in 2025, then retreated by 9.66% to -$114.5 million in 2026.
- Business Quant data shows IMMX's Retained Earnings at -$114.5 million in Q1 2026, -$104.5 million in Q4 2025, and -$93.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - | -114.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -114.55 Mn |
| Dec 31, 2025 | -104.46 Mn |
| Sep 30, 2025 | -93.78 Mn |
| Jun 30, 2025 | 90.87 Mn |
| Mar 31, 2025 | 15,463.00 |
| Dec 31, 2024 | -1,056.00 |
| Sep 30, 2024 | 87.67 Mn |
| Jun 30, 2024 | 116,972.00 |
| Mar 31, 2024 | 89,614.00 |
| Dec 31, 2023 | 134,666.00 |
| Sep 30, 2023 | -48.32 Mn |
| Jun 30, 2023 | 57.29 Mn |
| Mar 31, 2023 | 82,547.00 |
| Dec 31, 2022 | -37.99 Mn |
| Sep 30, 2022 | -34.19 Mn |
| Jun 30, 2022 | 50.71 Mn |
| Mar 31, 2022 | 50.60 Mn |
| Dec 31, 2021 | -29.76 Mn |
| Dec 31, 2020 | -5.37 Mn |